Overview
Deallus provides consulting services for the life sciences and healthcare sectors. It helps pharmaceutical, biotechnology, medical device, and healthcare companies with research-driven strategic support, including competitive intelligence, market analyses, pipeline and product strategy, and due diligence for mergers, partnerships, or investments. Its offerings translate scientific and market data into actionable insights through customized reports, dashboards, and advisory services. What sets Deallus apart is its focus on life sciences and health care, combining deep scientific understanding with intelligence and strategy work to deliver targeted, decision-ready analysis. The company aims to help clients make informed, faster decisions to maximize value in drug development, commercialization, and healthcare products.
Work here?Claim your company
Simplify's take
What believers are saying
- GlobalData is actively leveraging Deallus inside healthcare M&A since January 2025.
- Deallus careers page updated 22 September 2026, signaling continued hiring and operational activity.
- Fresh 2026 thought leadership on AI and competitive readiness supports lead generation.
What critics are saying
- GlobalData integration can dilute Deallus brand and autonomy throughout 2026.
- AI-enabled rivals commoditize CI deliverables, pressuring Deallus pricing and margins.
- Employee departure after Archimed exit and GlobalData consolidation can hollow out domain expertise.
What makes Deallus unique
- Deallus owns deep life-sciences CI expertise across oncology, neuroscience, vaccines, and rare diseases.
- GlobalData completed Deallus acquisition on 31 December 2024, expanding analytics distribution.
- Deallus still markets boutique, client-facing competitive readiness training and embedded strategic intelligence.
Help us improve and share your feedback! Did you find this helpful?